INTRODUCTION
Anti-vascular endothelial growth factor (anti-VEGF) has been reported as an additional treatment for neovascular glaucoma (NVG) [1] [2] [3] [4] . Off-label use of intravitreal injection of bevacizumab (IVB; Avastin Ò , Genentech, Inc., San Francisco, CA, USA) effectively reduces neovascularization in ocular tissues including NVG [5] . It resulted in regression of iris rubeosis, which is theoretically beneficial as a surgical adjuvant to reduce intraoperative bleeding during trabeculectomy [3, 4] . The mechanism of action of anti-VEGF was hypothesized to improve surgical outcome after conventional trabeculectomy [3, 6, 7] . There were no severe ocular and systemic side effects found with 
RESULTS
Fifteen eyes from 14 patients were enrolled in this study. Eight patients were male and six were female with a mean age of 65 years. The demographic and preoperative data are presented in Table 3 .
DISCUSSION
The present study demonstrates that IVR administered before conventional TMC results in rapid regression of NVI and subsequently reduces the chance of intraoperative bleeding.
Ranibizumab is an anti-VEGF which inhibits angiogenic activity and fibroblast proliferation.
Both effects are critical for ocular neovascularization and wound modulation.
The key success for NVG management is to There were only 2 eyes which were considered as failures (IOP more than 21 mmHg with maximal medication treatment). A patient with bilateral NGV had one successful eye and one eye which failed. The failed eye was the eye for which the surgeon could not apply PRP before or after TMC due to a corneal scar and vitreous hemorrhage. This eye was considered as more severely affected and having a poorer prognosis when compared to the first operated eye. Cyclodestruction was then applied. The other eye which failed was an eye with history of proliferative diabetic retinopathy and already showed the evidence of adequate PRP before IVR. This eye finally developed a new vitreous hemorrhage and underwent additional PRP with glaucoma drainage device implantation. Although IVR-augmented TMC could reserve vision at least equal to that at presentation in Laser suture lysis 11
5-FU injection 6
Bleb needling with 5-FU injection 4
Glaucoma drainage implantation 1 Cyclophotocoagulation 1 5 FU5 fluorouracil, IOP intraocular pressure, IVR intravitreal ranibizumab, TMC trabeculectomy with mitomycin C, PRP panretinal photocoagulation Table 3 Characteristics of individual eyes before and after TMC augmented with preoperative IVR in patients with NVG 
